Patients with the HR+/HER-2- subtype had the highest survival rate (survival rate of 92.5% at 4 years), followed by those with the HR+/HER-2+ subtype (90.3%), HR-/HER2+ subtype (82.7%), while patients with triple-negative breast cancer had the lowest survival rate (77.0%, including early- and advanced-stage patients), which dropped to 11.2% among triple-negative breast cancer patients with stage IV [29]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.